These findings also highlight the potential efficacy of EZH2 inhibitors for treatment of certain PCa subtypes but their limited efficacy for others, thus reinforcing the significance of tailoring therapeutic approaches. The gene discussed is EZH2; the disease is posterior cortical atrophy.